{
  "metadata": {
    "case_id": 25,
    "model": "GPT-5.1",
    "timestamp": "2025-11-29T15:22:47.885400",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/25_NCT04588480.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/25_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.9,
          0.18
        ],
        [
          0.25,
          0.96
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "label": "BNT162b2",
            "type": "EXPERIMENTAL",
            "description": "BNT162b2 (intramuscular injection)",
            "interventionNames": [
              "Biological: BNT162b2"
            ]
          },
          "pred_item": {
            "label": "BNT162b2",
            "type": "EXPERIMENTAL",
            "description": "Participants were randomized 3:1 to receive 2 intramuscular injections of 30 μg BNT162b2 administered 21 days apart. Healthy Japanese adults aged 20–85 years, including those with stable preexisting disease, were included.",
            "interventionNames": [
              "BNT162b2 30 μg",
              "Intramuscular injection procedures"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Placebo (intramuscular injection)",
            "interventionNames": [
              "Other: Placebo"
            ]
          },
          "pred_item": {
            "label": "Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Participants were randomized 3:1 to receive 2 intramuscular injections of placebo (saline) administered 21 days apart. Healthy Japanese adults aged 20–85 years, including those with stable preexisting disease, were included.",
            "interventionNames": [
              "Placebo (saline) injection",
              "Intramuscular injection procedures"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.96,
          0.15,
          0.78
        ],
        [
          0.18,
          0.96,
          0.7
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "BNT162b2",
            "description": "BNT162b2 (intramuscular injection)",
            "armGroupLabels": [
              "BNT162b2"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "BNT162b2 30 μg",
            "description": "BNT162b2 is a lipid nanoparticle formulation containing nucleoside-modified messenger RNA encoding the conformationally stabilized full-length SARS-CoV-2 spike glycoprotein. In this study it was administered as 2 intramuscular injections of 30 μg each, 21 days apart.",
            "armGroupLabels": [
              "BNT162b2"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "OTHER",
            "name": "Placebo",
            "description": "Placebo (intramuscular injection)",
            "armGroupLabels": [
              "Placebo"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo (saline) injection",
            "description": "Placebo consisting of saline solution, administered as 2 intramuscular injections 21 days apart, matching the BNT162b2 schedule and appearance.",
            "armGroupLabels": [
              "Placebo"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 14,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.78,
          0.05
        ],
        [
          0.78,
          0.12
        ],
        [
          0.72,
          0.15
        ],
        [
          0.68,
          0.15
        ],
        [
          0.78,
          0.12
        ],
        [
          0.78,
          0.12
        ],
        [
          0.55,
          0.08
        ],
        [
          0.4,
          0.05
        ],
        [
          0.62,
          0.06
        ],
        [
          0.4,
          0.12
        ],
        [
          0.4,
          0.1
        ],
        [
          0.68,
          0.08
        ],
        [
          0.08,
          0.96
        ],
        [
          0.18,
          0.96
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.78,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1",
            "description": "Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\\>) 2.0 to 5.0 cm, moderate: \\>5.0 to 10.0 cm, severe: \\>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.",
            "timeFrame": "Within 7 days after Dose 1"
          },
          "pred_item": {
            "measure": "Safety and tolerability of 2 doses of 30 µg BNT162b2",
            "description": "Incidence, severity, and relatedness of local reactions, systemic events, adverse events, serious adverse events, life‑threatening adverse events, deaths, and adverse events leading to discontinuation after two intramuscular doses of 30 µg BNT162b2 or placebo.",
            "timeFrame": "From dose 1 through 1 month after dose 2 (with serious adverse events planned to be collected through 12 months after dose 2; this report covers up to 1 month after dose 2)."
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 2",
            "description": "Local reactions included pain at injection site, redness and swelling and were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: \\> 2.0 to 5.0 cm, moderate: \\>5.0 to 10.0 cm, severe: \\>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.",
            "timeFrame": "Within 7 days after Dose 2"
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 1",
            "description": "Systemic events were recorded by participants in e-diary. Fever was categorized as greater than or equal to (\\>=)37.5 to 38.4 degrees(deg) Celsius(C), \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \\>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.",
            "timeFrame": "Within 7 days after Dose 1"
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 2",
            "description": "Systemic events were recorded by participants in an e-diary. Fever was categorized as \\>= 37.5 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24h, moderate: \\>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.",
            "timeFrame": "Within 7 days after Dose 2"
          },
          "pred_item": null
        },
        {
          "ref_idx": 4,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Adverse Events (AEs) From Dose 1 up to 1 Month After Dose 2",
            "description": "An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 95% confidence interval (CI) based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.",
            "timeFrame": "Dose 1 up to 1 month after Dose 2"
          },
          "pred_item": null
        },
        {
          "ref_idx": 5,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 up to 12 Months After Dose 2",
            "description": "SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or considered an important medical event. Percentage of participants with SAEs and the associated 95% CI based on the Clopper and Pearson method was presented.",
            "timeFrame": "Dose 1 up to 12 months after Dose 2"
          },
          "pred_item": null
        },
        {
          "ref_idx": 6,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 1 Day After Dose 1 by Age Category",
            "description": "The pre-defined criteria for laboratory parameters included: hemoglobin (HGB), hematocrit, erythrocytes(ery.) less than (\\<)0.8\\* lower limit of normal (LLN); ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \\<0.9\\*LLN and \\>1.1\\*upper limit of normal (ULN); platelets \\<0.5\\*LLN and \\>1.75\\*ULN; leukocytes \\<0.6\\*LLN and \\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN and \\>1.2\\*ULN; basophils, eosinophils, monocytes \\>1.2\\*ULN; bilirubin \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \\>3.0\\*ULN; urea nitrogen, creatinine \\>1.3\\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.",
            "timeFrame": "Within 1 day after Dose 1"
          },
          "pred_item": null
        },
        {
          "ref_idx": 7,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 1 by Age Category",
            "description": "The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \\<0.8\\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \\<0.9\\*LLN and \\>1.1\\*ULN; platelets \\<0.5\\*LLN and \\>1.75\\*ULN; leukocytes \\<0.6\\*LLN and \\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN and \\>1.2\\*ULN; basophils, eosinophils, monocytes \\>1.2\\*ULN; bilirubin \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \\>3.0\\*ULN; urea nitrogen, creatinine \\>1.3\\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.",
            "timeFrame": "Within 7 days after Dose 1"
          },
          "pred_item": null
        },
        {
          "ref_idx": 8,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 2 by Age Category",
            "description": "The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \\<0.8\\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \\<0.9\\*LLN and \\>1.1\\*ULN; platelets \\<0.5\\*LLN and \\>1.75\\*ULN; leukocytes \\<0.6\\*LLN and \\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN and \\>1.2\\*ULN; basophils, eosinophils, monocytes \\>1.2\\*ULN; bilirubin \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \\>3.0\\*ULN; urea nitrogen, creatinine \\>1.3\\*ULN. Categories with at least 1 non-zero data value were reported (only 65-85 years: Lymphocytes category was reported).",
            "timeFrame": "Within 7 days after Dose 2"
          },
          "pred_item": null
        },
        {
          "ref_idx": 9,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 1 Day After Dose 1 by Age Category",
            "description": "Hematology parameters: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, white blood cell (WBC) decrease, WBC increase. Chemistry parameters: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, blood urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in Grade from baseline to 1 day after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.",
            "timeFrame": "From baseline (observation prior to Dose 1) up to 1 day after Dose 1"
          },
          "pred_item": null
        },
        {
          "ref_idx": 10,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 7 Days After Dose 1 by Age Category",
            "description": "Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from baseline to 7 days after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.",
            "timeFrame": "From baseline (observation prior to Dose 1) up to 7 days after Dose 1"
          },
          "pred_item": null
        },
        {
          "ref_idx": 11,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Before Dose 2 to 7 Days After Dose 2 by Age Category",
            "description": "Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3= severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from before dose 2 to 7 days after dose 2 were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.",
            "timeFrame": "Before Dose 2 up to 7 days after Dose 2"
          },
          "pred_item": null
        },
        {
          "ref_idx": 12,
          "pred_idx": 1,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "Geometric Mean Titers (GMTs) of SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 2",
            "description": "GMT of SARS-CoV-2 neutralizing titer was calculated by exponentiating the mean logarithm of the titers and the corresponding 95% confidence interval (CI) was based on the Student's t distribution. GMT of SARS-CoV-2 neutralization titer 50% (NT50) was reported in this outcome measure.",
            "timeFrame": "1 month after Dose 2"
          },
          "pred_item": {
            "measure": "SARS-CoV-2 serum neutralizing antibody response 1 month after dose 2",
            "description": "Geometric mean titers (GMTs) of SARS‑CoV‑2 50% neutralizing antibody and geometric mean fold rises (GMFRs) in serum, measured using a SARS‑CoV‑2 mNeonGreen reporter virus neutralization assay, comparing post‑vaccination titers with baseline.",
            "timeFrame": "Baseline (before dose 1) to 1 month after dose 2."
          }
        },
        {
          "ref_idx": 13,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Geometric Mean Fold Rises (GMFRs) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After Dose 2",
            "description": "GMFR was defined as the result after vaccination divided by the result before vaccination. GMFR and the corresponding 2-sided 95% CIs was calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFR of SARS-CoV-2 NT50 was reported in this outcome measure.",
            "timeFrame": "Before vaccination up to 1 month after Dose 2"
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.82,
          0.86
        ],
        [
          0.78,
          0.82
        ],
        [
          0.9,
          0.9
        ],
        [
          0.82,
          0.8
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "measure": "GMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2",
            "description": "GMTs of SARS-CoV-2 neutralizing titers were calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution. GMTs of SARS-CoV-2 NT50 and neutralization titer 90% (NT90) were reported in this outcome measure.",
            "timeFrame": "NT50: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days after Dose 2"
          },
          "pred_item": {
            "measure": "SARS-CoV-2 serum neutralizing antibody response 14 days after dose 2",
            "description": "Geometric mean titers (GMTs) of SARS‑CoV‑2 50% neutralizing antibody and geometric mean fold rises (GMFRs) from baseline to 14 days after the second dose, assessed using a SARS‑CoV‑2 mNeonGreen reporter virus neutralization assay.",
            "timeFrame": "Baseline (before dose 1) to 14 days after dose 2."
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "GMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2",
            "description": "GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFRs of SARS-CoV-2 NT50 and NT90 were reported in this outcome measure.",
            "timeFrame": "NT50: Before vaccination up to 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2"
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "GMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2",
            "description": "GMTs of SARS-CoV-2 neutralizing titers was planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution.",
            "timeFrame": "Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 1, 6 and 12 months after Dose 2"
          },
          "pred_item": {
            "measure": "SARS-CoV-2 serum neutralizing antibody response 7 days after dose 2",
            "description": "Geometric mean titers (GMTs) of SARS‑CoV‑2 50% neutralizing antibody and geometric mean fold rises (GMFRs) from baseline to 7 days after the second dose, assessed using a SARS‑CoV‑2 mNeonGreen reporter virus neutralization assay.",
            "timeFrame": "Baseline (before dose 1) to 7 days after dose 2."
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "GMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2",
            "description": "GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution).",
            "timeFrame": "Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2 and 1, 6 and 12 months after Dose 2"
          },
          "pred_item": null
        }
      ]
    }
  ]
}